Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Chacón-Ovejero, B; Pacheco-Barcia, V; Palka-Kotlowska, M; Custodio-Cabello, S; Guerra-Hernandez, R; Jimenez-Fonseca, P; Muñoz-Martin, A; Gómez-Cerezo, JF; Cabezón-Gutiérrez, L.

Beyond body surface area: CT-derived body composition as a predictor of chemotherapy toxicity and survival in pancreatic ductal adenocarcinoma: a systematic review

CANCER TREATMENT REVIEWS. 2026; 148: Nº de citas: 1 [doi:10.1016/j.ctrv.2026.103174]

Pelegrín-Mateo, FJ; Mirete, BG; Mazón, FV; Lescure, AR; Fonseca, PJ; Bayonas, AC; Pérez, IF; Pérez, JR; Morán, LO; Lavin, DC; del Prado, PM; Marín, MM; de Herreros, MG; Campos, MC; Martin, AM.

Cancer-Associated Thrombosis in Genitourinary Malignancies: A Real-World Analysis From the TESEO Registry

ARCHIVOS ESPANOLES DE UROLOGIA. 2026; 79(6): 905-914 [doi:10.56434/j.arch.esp.urol.20267906.106]

Aguilar, A; Cobo, M; Calles, A; Azkarate, A; Gonzalez-Cao, M; Molina-Vila, MA; Rosell, R.

Phase Ib of repotrectinib plus osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer

LUNG CANCER. 2026; 217: [doi:10.1016/j.lungcan.2026.109461]

Riveiro-Barciela, M; Esteban, P; Vega-Cano, KS; Mateos, B; Miranda, EL; Jara, P; Martin, M; López, SA; Salcedo, M; Forns, X; Garcia-Fructuoso, I; Martinez-Sáez, O; Pinazo-Bandera, J; Garcia-Cortés, M; Ribelles, N; Nanclares, AR; Morchón-Araujo, D; Rodriguez, CA; Lozano, R; Dominguez-Gómez, R; Cejuela, M; Torres-Sempere, J; Ruiz-Cobo, JC; Villagrasa, A; Zamora, E; Buti, M; Bellet, M.

Clinical features and management for CDK4/6 inhibitor-DILI

JHEP Reports. 2026; 8(7): [doi:10.1016/j.jhepr.2026.101873]

Di Grazia, G; Di Lauro, V; Morchón-Araujo, D; Nucera, S; Figuero-Pérez, L; Calleja-Holgado, FJ; Sánchez, DP; Wallbaum, B; Vargas, PR; Palleschi, M; Musolino, A; Cobos, GZ; Paradís, AL; Barroso, G; Cano, OC; Portulas, ED; Caltavituro, A; Buono, G; Gillaranz, YJ; Echavarría, I; López-Tarruella, S; Sirvén, MB; Martínez-Sáez, O; Adamo, B; Mateu, MM; Arpino, G; Bayona, RS; De Laurentiis, M; Rodríguez, CA; Pascual, T; Losada, MV; Schettini, F.

Association between chemotherapy use and prognosis in young patients with stage I-II ER+ /HER2-negative breast cancer according to Prosigna®: An international real-world analysis with propensity-score matching

EUROPEAN JOURNAL OF CANCER. 2026; 242: Nº de citas: 1 [doi:10.1016/j.ejca.2026.116818]

Harris, WP; García-Alfonso, P; Metges, JP; Cubillo-Gracian, A; Zaanan, A; Carlos, LL; Ronzoni, M; Ponz-Sarvise, M; Baakili, A; Kefsi, A; Andrieu, L; Agrawal, M; Wang, WT; Paehler, T; Abbadessa, G; Van Cutsem, E.

Evaluating pegenzileukin (SAR444245/THOR-707) in combination with pembrolizumab or cetuximab in advanced metastatic gastrointestinal cancer: the PEGATHOR phase 2 study

INVESTIGATIONAL NEW DRUGS. 2026; : [doi:10.1007/s10637-026-01622-2]

Fernández-Fernández, I; Castro-Sánchez, E; Rodríguez-Calero, MA; Bujalance-Hoyos, J; Cobo-Sánchez, JL; Parra-García, G; Cubero-Pérez, MA; García-Garrido, JM; Blanco-Mavillard, I.

Variability in Vascular Access Device Use, Dwell Time and Failure: Insights From Routine Nursing Documentation in a Multicentre Cohort Study

JOURNAL OF CLINICAL NURSING. 2026; : [doi:10.1111/jocn.70397]

Rutkowski, P; Kowalski, DM; Moreno, V; Calvo, A; Thistlethwaite, F; Plummer, R; Steinbach, D; Loffredo, J; Akapeme, S; Jonathan, D; Philip, V; Girvin, A; Hampras, S; Hellemans, P; Bulat, I.

A phase I study evaluating subcutaneous administration of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced solid malignancies

CANCER IMMUNOLOGY IMMUNOTHERAPY. 2026; 75(9): [doi:10.1007/s00262-026-04457-1]

Dieras V; Curigliano G; Martin M; Lerebours F; Tsurutani J; Savard MF; Jerzak KJ; Hu X; Martins de Aquino Pimentel LC; O'Sullivan CC; Tokunaga E; Okines A; Huang CS; Jacot W; Sohn J; Cronemberger Silva E; Mueller V; Yang S; Granata G; Shen Q; Santarpia L; Hamilton E.

HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer.

JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(17): 1597-1607 Nº de citas: 24 [doi:10.1200/JCO-25-02600]

Torres-Jiménez, J; Fuentes, JDB; Morales, MG; Ozores, PP; Ruiz-Casado, AI; Vieito, M; Serrano-Gómez, C; Esteban-Villarrubia, J; Calvo, A; Garralda, E; Moreno, V; Corbacho, JG; Martin-Liberal, J; Sarrió, RG.

Inequities in enrollment across clinical trial phases and the need for a Spanish perspective

Clinical & Translational Oncology. 2026; : [doi:10.1007/s12094-026-04428-z]

Muñoz-Casares, FC; Gómez-Barbadillo, J; Alvarez-Alvarez, R; Hindi, N; Sebio, A; Lozano-Lominchar, P; Fernández-Hernández, JA; Vasques, H; Muñoz-Muñoz, P; Asencio-Pascual, JM.

Surgical Management and Therapeutic Strategy of Uterine Sarcoma According to Histological Subtype and Staging: Updated Review and Recommendations

Cancers. 2026; 18(12): [doi:10.3390/cancers18121870]

Motzer, RJ; Albiges, L; Aguirre, SAT; Kanesvaran, R; Centkowski, P; Reimers, MA; Sade, JP; Pouessel, D; Biscaldi, E; Esteban, E; Arija, JAA; Tykodi, SS; Losio, MV; Dighe, A; Ma, H; Valmeekam, V; Simmons, A; Scheffold, C; Andrianova, S; Braun, DA; Powles, T; Choueiri, TK.

Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study

ANNALS OF ONCOLOGY. 2026; 37(6): 861-871 Nº de citas: 4 [doi:10.1016/j.annonc.2026.02.011]

Fakih, M; Gill, S; Sampat, K; Chan, DL; Fisher, G; Cruz-Correa, M; Lenz, HJ; Garcia-Alfonso, P; Forget, F; Lonardi, S; Krauss, J; Chen, E; Gracian, AC; Liu, Y; van Buuren, N; Shao, J; Dong, M; Chen, A; Tejani, M; Hecht, JR.

Phase II randomised study of magrolimab combined with bevacizumab-FOLFIRI in patients with previously treated advanced inoperable metastatic colorectal cancer

ESMO Gastrointestinal Oncology. 2026; 12: [doi:10.1016/j.esmogo.2026.100324]

Servitja, S; Carrasco, E; Andrés, R; Rodríguez-Lescure, A; Martín, M; Ruiz-Borrego, M; Guerrero, A; Bermejo, B; Antón, A; Muñoz, M; Margeli, M; Alvarez, I; Fernández, LA; Ponce, J; Cruz, J; Martínez, P; López-Tarruella, S; Amenedo, M; Blasco, A; Polonio, O; Gil-Gil, M.

Outcomes of Hormone receptor-positive/HER2-negative early breast cancer patients by risk of recurrence groups focusing on the intermediate-risk group: Retrospective analysis from GEICAM studies

BREAST CANCER RESEARCH. 2026; 28(1): [doi:10.1186/s13058-026-02300-0]

Peters, S; Tan, DSW; Gerber, DE; Urbanic, J; Ramalingam, S; Yu, JM; Xing, LG; Rittmeyer, A; Ciuleanu, TE; de Menezes, J; Kim, HR; Rojas, C; Syrigos, K; Hayashi, H; Haridass, A; Cortinovis, D; Bruno, D; Kimmich, M; Calles, A; Nathani, R; Pudussery, G; Yang, LY; De Ruysscher, D.

Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trial

Nature Cancer. 2026; 7(7): Nº de citas: 2 [doi:10.1038/s43018-026-01161-y]

Sharma, P; Krainer, M; Saad, F; Castellano, D; Bedke, J; Kwiatkowski, M; Patnaik, A; Procopio, G; Wiechno, P; Kochuparambil, S; Thomas, C; Arija, JAA; McCune, SL; Hansen, S; Daugaard, G; Mingorance, JID; Kukard, C; Subudhi, SK; Basu, S; Jindal, S; Siddiqui, BA; Lako, A; Gupta, S; Fedorov, V; Amin, NP; Campos, A; Wang, YM; David, JM; Pachynski, RK.

Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial

Nature Communications. 2026; 17(1): Nº de citas: 1 [doi:10.1038/s41467-026-72242-w]

García-Campelo, MR; Corral, J; Moreno, F; Munoz, A; Balea, JM; Barragán, B; Ginés, J; Nicolás, FG; Sangro, B; Martin-Sánchez, EM; Trapero-Bertran, M.

Challenges in the measurement and valuation of oncological treatments in Spain: recommendations and call to action

Clinical & Translational Oncology. 2026; : [doi:10.1007/s12094-026-04323-7]

Pena-Burgos, EM; Suárez-González, J; Muñoz, LH; Valles, MA; Asencio, JM; Mora-Díaz, R; Pozo-Kreilinger, JJ.

STRN::NTRK3-fused neoplasm with "monster cells" in the pelvis of a young adult female: expanding the clinicopathologic spectrum of NTRK-rearranged neoplasms

VIRCHOWS ARCHIV. 2026; : [doi:10.1007/s00428-026-04551-w]